Vistin Pharma ASA (VISTN) - Cash Flow Conversion Efficiency

Latest as of June 2025: 0.022x

Based on the latest financial reports, Vistin Pharma ASA (VISTN) has a cash flow conversion efficiency ratio of 0.022x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Nkr6.37 Million ≈ $669.89K USD) by net assets (Nkr294.27 Million ≈ $30.97 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Vistin Pharma ASA (VISTN) balance sheet quality index to measure how much of total assets are equity-financed.

Vistin Pharma ASA - Cash Flow Conversion Efficiency Trend (2016–2024)

This chart illustrates how Vistin Pharma ASA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Vistin Pharma ASA earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.

Vistin Pharma ASA Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Vistin Pharma ASA ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Eolus Vind AB (publ) ST:EOLU-B	0.793x
Technical Olympic S.A AT:OLYMP	-0.002x
AKA Brands Holding Corp NYSE:AKA	-0.041x
TTEC Holdings Inc NASDAQ:TTEC	0.269x
MIC Electronics Limited NSE:MICEL	0.001x
Micware Co., Ltd. American Depositary Shares NASDAQ:MWC	N/A
Pelican Acquisition Corporation Ordinary Shares NASDAQ:PELI	-0.001x
Data Communications Management Ltd TO:DCM	0.347x

Annual Cash Flow Conversion Efficiency for Vistin Pharma ASA (2016–2024)

The table below shows the annual cash flow conversion efficiency of Vistin Pharma ASA from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see Vistin Pharma ASA market cap and net worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	Nkr309.53 Million ≈ $32.57 Million	Nkr107.86 Million ≈ $11.35 Million	0.348x	+24.15%
2023-12-31	Nkr322.77 Million ≈ $33.96 Million	Nkr90.59 Million ≈ $9.53 Million	0.281x	+964.87%
2022-12-31	Nkr273.26 Million ≈ $28.76 Million	Nkr-8.87 Million ≈ $-933.17K	-0.032x	-165.44%
2021-12-31	Nkr275.89 Million ≈ $29.03 Million	Nkr13.68 Million ≈ $1.44 Million	0.050x	+109.27%
2020-12-31	Nkr272.40 Million ≈ $28.66 Million	Nkr-145.73 Million ≈ $-15.34 Million	-0.535x	-1267.99%
2019-12-31	Nkr413.40 Million ≈ $43.50 Million	Nkr18.93 Million ≈ $1.99 Million	0.046x	+140.47%
2018-12-31	Nkr348.85 Million ≈ $36.71 Million	Nkr-39.48 Million ≈ $-4.15 Million	-0.113x	-243.02%
2017-12-31	Nkr120.16 Million ≈ $12.64 Million	Nkr9.51 Million ≈ $1.00 Million	0.079x	-72.57%
2016-12-31	Nkr186.61 Million ≈ $19.64 Million	Nkr53.84 Million ≈ $5.67 Million	0.288x	--

About Vistin Pharma ASA

OL:VISTN Norway Drug Manufacturers - Specialty & Generic

Market Cap

$95.66 Million

Nkr909.06 Million NOK

Market Cap Rank

#19338 Global

#175 in Norway

Share Price

Nkr20.50

Change (1 day)

+2.50%

52-Week Range

Nkr19.70 - Nkr24.60

All Time High

Nkr28.06